Catalog No.
RHB87801
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, lambda
Clonality
Monoclonal
Target
Coagulation factor IX, 3.4.21.22, Christmas factor, Plasma thromboplastin component, PTC, Coagulation factor IXa light chain, Coagulation factor IXa heavy chain, F9
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00740
Applications
Blocking, ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
10C12
Multiplex and multimodal mapping of variant effects in secreted proteins via MultiSTEP., PMID:40514537
Multiplex, multimodal mapping of variant effects in secreted proteins., PMID:39975210
Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia B: a case report., PMID:39609856
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives., PMID:39062568
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)., PMID:37962325
Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients., PMID:37722393
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications., PMID:35842956
The Clinical Genetics of Hemophilia B (Factor IX Deficiency)., PMID:34848993
Molecular analysis of severe hemophilia B in Indian families: Identification of mutational hotspot and novel variants., PMID:34590426
Haemophilia., PMID:34168126
Identification of zebrafish ortholog for human coagulation factor IX and its age-dependent expression., PMID:33974340
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)., PMID:33278853
Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations., PMID:32875744
The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges., PMID:32726826
Advances and challenges for hemophilia gene therapy., PMID:31332444
Gene Therapy for Hemophilia: Progress to Date., PMID:29127625
Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B., PMID:28007939
Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations., PMID:26612714
Risk factors associated with inhibitor development in Chinese patients with haemophilia B., PMID:25929987
Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B., PMID:25470321
Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4., PMID:25417755
[Haemophilia]., PMID:25351381
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B., PMID:24460861
Mutation analysis of a cohort of US patients with hemophilia B., PMID:24375831
Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B., PMID:23093250
Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B., PMID:22279442
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity., PMID:22103590
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B., PMID:19603001
Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer., PMID:19309290
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy., PMID:15231566
Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors., PMID:11545612
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9., PMID:11545610
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation., PMID:11545609
For research use only. Not for human or drug use.
